Tipharco Pharmaceutical Joint Stock Company (DTG) explains to shareholders the fluctuations in revenue and profit after tax in the Financial Statement for Q4 2024 compared to the same period in 2023 as follows:
At the time of Q4/2024, net revenue reached VND 148.4 billion, up 18% over the same period in 2023 (VND 126.2 billion). Profit in the period reached about 10.1 billion, equivalent to a decrease of nearly 21%.
The reason for the fluctuation in revenue and profit mainly comes from the general difficulties of the pharmaceutical market. In order to improve the business situation, the company diversified its distribution channels and expanded its customer base, and developed a more flexible sales policy to meet the needs of new customers.
In addition, in 2024, the comprehensive upgrade and overhaul process at the Tan Duoc factory has led to a number of increased costs compared to the same period in 2023. This is the main reason for the increase in abnormal business management costs, indirectly causing a decline in profits in 2024.
In the coming time, the Board of Directors will continue to develop and implement solutions to promote sales, manage costs effectively, and be ready for growth when the market has positive changes.
For more information, please see the attached file:
- Explanation of Quarter 4 Financial Statements;
- Financial Statement Q4 2024